16 results on '"Liao, Xiong-yu"'
Search Results
2. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, Li, Yang, Huang, Ke, Xu, Hong-gui, Fang, Jian-pei, and Zhou, Dun-hua
- Published
- 2023
- Full Text
- View/download PDF
3. Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, Liu, Yong, Huang, Ke, Li, Yang, Fang, Jian-pei, and Zhou, Dun-hua
- Published
- 2022
- Full Text
- View/download PDF
4. Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study
- Author
-
Qiu, Kun-yin, Zhou, Dun-hua, Liao, Xiong-yu, Huang, Ke, Li, Yang, Xu, Hong-gui, Weng, Wen-jun, Xu, Lu-hong, and Fang, Jian-pei
- Published
- 2022
- Full Text
- View/download PDF
5. TARGET based m6A methylation-related genes predict prognosis relapsed B-cell acute lymphoblastic leukemia.
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, Fang, Jian-pei, and Zhou, Dun-hua
- Abstract
Purpose: The current study aims to investigate the significance of N6-methyladenosine (m
6 A) methylationrelated genes in the clinical prognosis of childhood relapsed B-cell acute lymphoblastic leukemia (B-ALLL) patient. Methods: Transcriptome data and corresponding clinical data on m6 A methylation-related genes (including 20 genes) were obtained from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) database. Results: The bone marrow (BM) samples of 134 newly diagnosed (naive) and 116 relapsed B-ALL from TARGET were enrolled in the current study. Three genes (FTO, HNRNPC, RBM15B) showed significant up-regulation in relapsed B-ALL compared with that in naive B-ALL.The three genes had a significantly worse survival (P < 0.05). The LASSO Cox regression model was used to select the most predictive genes as prognostic indicators, and YTHDC1 and FTO were identified as prognostic factors for relapsed B-ALL. Finally, the results of multivariate regression analysis showed that the risk score of m6 A methylation-related genes was an independent prognostic factor in relapsed B-ALL (P < 0.05). Conclusion: We found that the expression levels of m6 A methylation-related genes were different in naive and relapsed patients with B-ALL and correlated with survival and prognosis.This implies that m6 A methylation-related genes may be promising prognostic indicators or therapeutic targets for relapsed B-ALL. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, He, Zhan-wen, Wu, Ruo-hao, Li, Yang, Xu, Lu-hong, Zhou, Dun-hua, and Fang, Jian-pei
- Published
- 2021
- Full Text
- View/download PDF
7. Analysis of clinical characteristics and prognostic factors associated with EBV-associated HLH in children.
- Author
-
Qiu, Kun-yin, Guo, Shu-yi, Zeng, Yang-hui, Liao, Xiong-yu, Lin, Shao-fen, Fang, Jian-pei, and Zhou, Dun-hua
- Subjects
PROGNOSIS ,HEMOPHAGOCYTIC lymphohistiocytosis ,CHILD mortality ,UNIVARIATE analysis ,STATISTICAL correlation - Abstract
Purpose Our aim is to analyze the clinical characteristics and prognostic factors of Epstein-Barr (EB) virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in children. Methods Children with newly diagnosed HLH were retrospectively analyzed. Results Finally, a total of 95 children with HLH were enrolled in this study, including 43 (45.3%) with EBV-HLH and 52 (54.7%) with non-EBV-HLH. Laboratory tests showed that the levels of absolute neutrophil count (ANC) decrease (P = 0.031) and triglycerides (TG) increase (P = 0.036) in the EBV-HLH group were statistically significant compared with those in the non-EBV-HLH group, respectively. We found that the remission rate during induction period in the EBV-HLH group and non-EBV-HLH group was 75.8% and 89.3%, respectively. The correlation analysis showed that the elevated degree of total bilirubin (TBIL) (P = 0.042), triglyceride (TG) (P = 0.009), serum ferritin (SF) (P = 0.008) and interleukin-8 (IL-8) (P = 0.004) were related with the remission rate during induction in the EBV-HLH group. Further univariate analysis showed that the elevated degree of TBIL (P = 0.048) and TG (P = 0.019) were significant risk factors for the remission rate during induction in the EBV-HLH group. In the multivariate analysis, we observed that there was statistical significance for the degree of TG elevation (P = 0.015) between the two groups. The correlation analysis showed that the elevated degree of TBIL (P = 0.030), the elevated degree of SF (P = 0.020) and the elevated degree of interleukin-6 (P = 0.010) were related to the induction mortality of children with EBV-HLH. Conclusion TBIL and TG are valid indicators to assess the efficacy and prognosis of EVBHLH among children in induction period. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. CEBPA are independent good prognostic factors in pediatric acute myeloid leukemia.
- Author
-
Liao, Xiong‐yu, Fang, Jian‐pei, Zhou, Dun‐hua, and Qiu, Kun‐yin
- Subjects
ACUTE myeloid leukemia ,PROGNOSIS ,STEM cell transplantation ,CHILD patients ,OVERALL survival - Abstract
To evaluate the outcome and prognostic significance of CEBPA mutations among pediatric acute myeloid leukemia (AML) from TARGET dataset. A total of 1803 pediatric patients who were diagnosed with AML were classified into two groups based on the CEBPA status by using a retrospective cohort study method from September 1996 to December 2016. The incidence of CEBPA mutations was 18%. CEBPA mutations were significantly associated with elder age (p < 0.001), higher WBC (p = 0.004), higher proportion of peripheral blood blast (p < 0.001), normal karyotype (p < 0.001), low risk (p < 0.001) and higher complete remission induction rates (p < 0.05). Overall, CEBPA mutations patients had a significantly better 5‐year EFS (p < 0.001) and OS (p < 0.001) compared to CEBPA wild‐type patients, and this favorable impact was maintained even in the presence of FLT3/ITD mutations. Stem cell transplantation had no significant impact on the survival of patients with coexistence of CEBPA and FLT3/ITD mutations. Multivariate analysis demonstrated that mutated CEBPA were an independent favorable indicators of better outcome in terms of EFS (p = 0.007) and OS (p = 0.039). Our study demonstrate mutated CEBPA have an excellent outcome in pediatric AML patients. Furthermore, pediatric AML patients with coexistence of CEBPA and FLT3/ITD mutation appear to have favorable prognoses and might not required stem cell transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Eltrombopag as first‐line treatment for thrombocytopenia among paediatric patients after allogeneic haematopoietic stem cell transplantation.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Huang, Ke, Wu, Ruo‐hao, Xu, Hong‐gui, Xu, Lu‐hong, Li, Yang, Weng, Wen‐jun, Zhou, Dun‐hua, and Fang, Jian‐pei
- Subjects
- *
STEM cell transplantation , *CHILD patients , *PLATELET count , *ELTROMBOPAG , *DRUG efficacy , *THROMBOCYTOPENIA , *MULTIPLE regression analysis - Abstract
Aims: The purpose of this study is to examine the safety and efficacy of eltrombopag as first‐line treatment for thrombocytopenia among paediatric patients after haematopoietic stem cell transplantation (HSCT). Methods: Forty‐three childhood patients with thrombocytopenia after HSCT who received eltrombopag were retrospectively analysed. Result: Eltrombopag was began at the median of 27 days after HSCT and lasted for 24 days. Thirty‐five children responded to eltrombopag therapy, and the cumulative platelet recovery rate was 88.9%. The cumulative incidence of platelet recovery was lower (83.9 vs 100%; P =.035) in patients with decreased numbers of megakaryocytes before starting eltrombopag than in those with normal. Factors associated with a significantly elevated response to eltrobopag from univariate analysis were donor type. Results from the multiple regression analysis found that weight (hazard ratio [HR] = 0.7, 95% confidence interval [CI] 0.5–0.9, P =.022), platelet engraftment time (HR = 1.0, 95%CI 1.0–1.0, P =.012) and bone marrow megakaryocytes (HR = 8.0, 95%CI 1.5–43.3, P =.016) before starting eltrombopag were the independent risk factors. Based on Youden's index algorithm in the receiver‐operating characteristic curve, the optimal cut‐off value of the maintenance dose of eltrombopag in predicting nonresponders was 4 mg/kg. The area under the receiver‐operating characteristic curve was 0.923 with sensitivity of 97.8%, specificity of 87.9%, positive predictive value of 72.3%, and negative predictive value of 92%. None of the paediatric patients stopped using eltrombopag due to side effect or intolerability. Conclusion: Eltrombopag is effective and safe in paediatric patients with thrombocytopenia after HSCT. The number of megakaryocytes in bone marrow before eltrombopag treatment may serve as a predictor of the response to eltrombopag. We recommend that the maintenance dose of eltrombopag should not exceed 4 mg/kg/d. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Diagnosis and treatment of juvenile myelomonocytic leukemia.
- Author
-
Liao, Xiong-yu, Qiu, Kun-yin, Fang, Jian-pei, Wu, Ruo-hao, Guo, Shu-yi, Huang, Ke, and Zhou, Dun-hua
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *POOR children , *LEUKEMIA , *PROGRESSION-free survival - Abstract
Objective: To investigate clinical features, diagnosis, treatment strategies and prognosis of juvenile myelomonocytic leukemia (JMML). Methods: The clinical data of 21 patients with JMML who were diagnosed in our hospital from January 2013 to May 2018 were retrospectively analyzed. Results: Among the 21 children with JMML, 16 were male and 5 were female. Out of the 21 children who were diagnosed with JMML, 7 were lost after treatment while the remaining 14 received A-3V chemotherapy regimen of South Korea. The effective response rate was 78.5%. The three-year overall survival (OS) rate and three-year disease-free survival (DFS) rate were (76.2 ± 14.8)% and (66.2 ± 14)%, respectively. Single factor analysis showed that PLT count ≤33×109/L, LDH level >500 U/L and HbF level >10% and chemotherapy only were the significant factors that lead to poor prognosis in children. Cox multivariate analysis showed that the choice of treatment options affected the prognosis of JMML children. By taking prognostic factors for long-term efficacy into account, patients with treatment strategy of chemotherapy alongside hematopoietic stem cell transplantation (HSCT) have a better prognosis. Conclusion: The PLT count, LDH level, HbF level and choice of treatment plan are important for the evaluation of prognosis for children with JMML. Although there is a lack of consistency in terms of donors but the A-3V scheme is relatively stable, so HSCT should be preferred for children with poor prognostic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Atrial septal defect in a patient with congenital disorder of glycosylation type 1a: a case report.
- Author
-
Wu, Ruo-hao, Li, Dong-fang, Tang, Wen-ting, Qiu, Kun-yin, Li, Yu, Liao, Xiong-yu, Tang, Dan-xia, Qin, Li-jun, Deng, Bing-qing, and Luo, Xiang-yang
- Subjects
GENETIC disorders ,GLYCOSYLATION ,METABOLIC disorders ,DNA mutational analysis - Abstract
Background: Atrial septal defect often become more severe when encountered in genetic syndromes. Congenital disorder of glycosylation type 1a is an inherited metabolic disorder associated with mutations in PMM2 gene and can affect almost all organs. Cardiac abnormalities vary greatly in congenital disorder of glycosylation type 1a and congenital heart defects have already been reported, but there is little knowledge about the effect of this inherited disorder on an existing congenital heart defect. Herein we report for the first time on a baby with congenital disorder of glycosylation type 1a with atrial septal defect and make a comparison of changes in atrial septal defect by follow-ups to the age of 3.Case Presentation: Our patient was an 8-month-old Han Chinese boy. At the initial visit, he presented with recurrent lower respiratory infection, heart murmur, psychomotor retardation, inverted nipples, and cerebellar atrophy. Echocardiography revealed a 8 mm secundum atrial septal defect with left-to-right shunt (Qp/Qs ratio 1.6). Enzyme testing of phosphomannomutase 2 demonstrated decreased levels of phosphomannomutase 2 activities in fibroblasts. Whole exon sequencing showed he was heterozygous for a frameshift mutation (p.I153X) and a missense mutation (p.I132T) in PMM2 gene. The diagnosis of congenital disorder of glycosylation type 1a with atrial septal defect was issued. Now, he is 3-years old at the time of this writing, with the development of congenital disorder of glycosylation type 1a (cerebellar atrophy become more severe and the symptom of nystagmus emerged), the size of atrial septal defect increased to 10 mm and the Qp/Qs ratio increased to 1.9, which suggested exacerbation of the atrial septal defect. Congenital heart defect-associated gene sequencing is then performed and shows there are no pathogenic mutations, which suggested intrinsic cardiac factors are not the cause of exacerbation of the atrial septal defect in our patient and it is reasonable to assume congenital disorder of glycosylation type 1a can worsen the situation of the existing atrial septal defect.Conclusions: This report highlights the view that congenital disorders of glycosylation type 1a should be excluded when faced with congenital heart defect with cerebellar atrophy or neurodevelopmental delay, especially when the situation of congenital heart defect becomes more and more severe. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
12. X-linked Hyper-IgM Syndrome: A Phenotype of Crohn's Disease with Hemophagocytic Lymphohistiocytosis.
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, Wu, Ruo-hao, Huang, Ke, Fang, Jian-pei, and Zhou, Dun-hua
- Subjects
- *
IMMUNOGLOBULIN M , *CROHN'S disease , *LIGANDS (Biochemistry) , *CD40 antigen , *IMMUNODEFICIENCY - Abstract
X-linked hyper-immunoglobulin M (IgM) syndrome is characterized by recurrent infections, low or undetectable levels of IgG and IgA, and normal to increased serum IgM, and is also rare. It is associated with mutation in the gene encoding CD40 ligand. This study aimed to describe the first international report of hemizygous CD40LG c.542G>A mutation in a 5-year-old boy with a phenotype of Crohn's disease and hemophagocytic lymphohistiocytosis. Also, the clinical implications of this mutation and associated atypical phenotype are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. The early diagnostic value of serum galactomannan antigen test combined with chest computed tomography for invasive pulmonary aspergillosis in pediatric patients after hematopoietic stem cell transplantation.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Huang, Ke, Xu, Hong‐gui, Li, Yang, Fang, Jian‐pei, and Zhou, Dun‐hua
- Subjects
- *
PULMONARY aspergillosis , *HEMATOPOIETIC stem cell transplantation , *TOMOGRAPHY , *FEBRILE neutropenia - Abstract
Objective: The purpose of our study was to evaluate the diagnostic value of serum galactomannan antigen (GM) testing combined with chest computed tomography (CT) of invasive pulmonary aspergillosis (IPA) in pediatric patients after hematopoietic stem cell transplantation. Methods: A retrospective nested case‐control study was conducted in the identifying IPA among pediatric patients. Results: A total of 141 eligible pediatric recipients with febrile neutropenia were enrolled in this study. All patients in the cases were diagnosed with proven‐probable IPA(PP‐IPA), while only 9 patients in the controls. GM testing was positive in 38 pediatric recipients in the cases and nine recipients in the controls with sensitivity of 62.3%, specificity of 81.8%. Among all patients with IPA, 46 patients in the cases and 9 patients in the controls had typical features of CT imaging with sensitivity of 79.3%, specificity of 85.2%. For discrimination of participants' GM testing combined with CT evaluation, the AUC of the diagnostic model was 0.887 with PPV of 0.764, and NPV of 0.872. Sensitivity was 0.793, and specificity was 0.852 in IPA. Conclusion: The combination methods with serum GM and CT scan might be used as a valuable marker for early diagnosis of IPA in pediatric patients after HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
- Author
-
Qiu, Kun‐yin, Liao, Xiong‐yu, Fang, Jian‐pei, Xu, Hong‐gui, Li, Yang, Huang, Ke, and Zhou, Dun‐hua
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYCOSES , *THERAPEUTICS , *DRUG side effects , *POOR children - Abstract
Background: Invasive fungal disease (IFD) has a poor prognosis in children with hematological disorders after hematopoietic stem cell transplantation (HSCT). We assessed if drug combinations with different targets may improve the outcome. Methods: Retrospective study to assess the outcome of combination antifungal therapy (CAT) for proven‐probable IFD (PP‐IFD) in children with hematological disorders after HSCT from January 2008 to June 2018. Results: Over the 10‐year period, 95 PP‐IFD were diagnosed in pediatric recipients, median age of 5.6 years. Twenty‐seven patients received combinations of caspofungin and voriconazole, 28 patients received combinations of caspofungin and amphotericin B, and 40 patients received combinations of voriconazole and amphotericin B. The overall response rate of PP‐IFD was 77.9%, while the 100‐day overall survival rates were 66.8%. Univariate analysis showed that factors that significantly affected the response to combination treatments were type of combination (P = 0.02), the stem cell source (P = 0.04), the donor type (P = 0.03), HLA‐match (P = 0.03), aGVHD (P = 0.02), period of treatment (P = 0.044), use of corticosteroids (0.036), CD4:CD8 ratio (P = 0.014), and CMV viremia (P = 0.033). In addition, multivariate analysis demonstrated that only the type of combination remained a significant factor (odds ratio = 0.335, 95% confidence interval: 0.071‐0.812, P = 0.042). Forty‐three children suffered from mild and reversible adverse reactions, no serious side effects during treatment. Conclusion: A variety of factors can affect the outcome of CAT. Combination of caspofungin with voriconazole is a safe and helpful treatment option for HSCT recipients with IFD. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Coexistence of ETV6-RUNX1 and MLL aberration among pediatric acute lymphoblastic leukemia: case reports and a literature review.
- Author
-
Qiu KY, Liao XY, Huang K, Xu HG, Li Y, Zhou DH, and Fang JP
- Abstract
Background: It is known that ETV6 - RUNX1 is usually related to favorable prognosis, but MLL aberration has been associated with poor prognosis among pediatric acute lymphoblastic leukemia (ALL). However, the outcome of coexistence of ETV6 - RUNX1 and MLL aberration in pediatric ALL patients is unknown. Herein, we report 4 cases of the coexistence of ETV6 - RUNX1 and MLL -partial tandem duplications ( MLL -PTD) in pediatric ALL patients and show the favorable outcome, which was never reported before., Case Description: The frequency of coexistence of ETV6 - RUNX1 and MLL aberration at our children's medical center was calculated as 0.98% (4/410). All of them were ETV6 / RUNX1 -positive cases that exhibited MLL -PTD, and the 10-year event-free survival (EFS) and overall survival (OS) were both 75%. With the following keywords of " ETV6 - RUNX1 ", " MLL ", "children" and "acute lymphoblastic leukemia", a literature search of coexistence of ETV6 - RUNX1 and MLL aberration was conducted in the database of PubMed, and 4 articles were retrieved finally, involving 16 cases of children. Among the 16 cases of pediatric ALL, the age ranged from 2 to 7 years old, including 9 males and 7 females and the white blood cell (WBC) count was (2.66-68.6)×10
9 /L. In terms of fusion genes, they all had positive ETV6 / RUNX1 . Among them, MLL deletion was exhibited among 8 ETV6 / RUNX1 -positive patients, and 2 cases of der(21) duplication. MLL allelic deletions were shown among the remaining ETV6 / RUNX1 -positive patients. All patients showed a favorable outcome., Conclusions: The results of our analysis primarily provide compelling evidence that cases with an MLL -PTD or other types of MLL aberration are in fact a distinct subentry among ETV6 - RUNX1 B-cell ALL (B-ALL)., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-142/coif). The authors have no conflicts of interest to declare., (2023 Translational Cancer Research. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
16. Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway.
- Author
-
Liao XY, Zhou DH, Fang JP, and Qiu KY
- Abstract
Background: The childhood patients with mixed-lineage leukemia rearrangement (MLL-r) gene have worse outcome than non-MLL, and thus often treated with high-risk chemotherapy regimens, so targeted therapy is important for this type of leukemia. This purpose of study was to explore the effects of ruxolitinib on the proliferation, apoptosis, and cell cycle of Nalm-6 cells., Methods: In this study, human acute lymphoblastic leukemia (ALL) cell line Nalm-6 was used as the research object. By constructing an MLL overexpression vector to transfect Nalm-6 cells, exogenous JAK2/STAT3 signal pathway inhibitor ruxolitinib was applied to observe the proliferation, apoptosis, and cell cycle changes of the transfected Nalm-6 cells. Western blot was performed to determine the proteins (MLL-BP, JAK, STAT) involved in the mechanism of action of MLL-r leukemia. CCK8 assay and flow cytometry (FCM) were used for testing the proliferation and apoptosis among MLL-BP transfected Nalm-6 cells., Results: Firstly, we determine the IC50 of ruxolitinib on Nalm-6 cells. Secondly, FCM and CCK8 showed that ruxolitinib dosedependentlyinhibits proliferation of Nalm-6 cells by blocking the cell cycle at G
0 /G1 phase. In addition, FCM showed that ruxolitinib promoted the apoptosis of MLL-BP transfected Nalm-6 cells. Mechanistically, ruxolitinib inactivated JAK/STAT signaling pathway in MLL-BP transfected Nalm-6 cells, mediating ruxolitinib's inhibition of cell proliferation, and inducing apoptosis. Finally, ruxolitinib significantly inhibited the proliferation of MLL-r ALL cells and promoted their apoptosis., Conclusions: These data provide compelling evidence that ruxolitinib is a promising agent against MLL-r leukemia cell line. However, it needs going through multiple more steps to confirm before it can be an option in clinical practice., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-16/coif). The authors have no conflicts of interest to declare., (2023 Translational Pediatrics. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.